1. Home
  2. NXL vs XTKG Comparison

NXL vs XTKG Comparison

Compare NXL & XTKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXL
  • XTKG
  • Stock Information
  • Founded
  • NXL 2010
  • XTKG 1997
  • Country
  • NXL United States
  • XTKG Singapore
  • Employees
  • NXL N/A
  • XTKG N/A
  • Industry
  • NXL Medical Specialities
  • XTKG
  • Sector
  • NXL Health Care
  • XTKG
  • Exchange
  • NXL Nasdaq
  • XTKG NYSE
  • Market Cap
  • NXL 10.0M
  • XTKG 8.5M
  • IPO Year
  • NXL 2022
  • XTKG 2019
  • Fundamental
  • Price
  • NXL $2.87
  • XTKG $0.61
  • Analyst Decision
  • NXL Hold
  • XTKG
  • Analyst Count
  • NXL 1
  • XTKG 0
  • Target Price
  • NXL N/A
  • XTKG N/A
  • AVG Volume (30 Days)
  • NXL 377.2K
  • XTKG 102.4K
  • Earning Date
  • NXL 03-26-2025
  • XTKG 11-27-2024
  • Dividend Yield
  • NXL N/A
  • XTKG N/A
  • EPS Growth
  • NXL N/A
  • XTKG N/A
  • EPS
  • NXL N/A
  • XTKG N/A
  • Revenue
  • NXL $162,078.00
  • XTKG $15,234,138.00
  • Revenue This Year
  • NXL $56.86
  • XTKG N/A
  • Revenue Next Year
  • NXL $167.44
  • XTKG N/A
  • P/E Ratio
  • NXL N/A
  • XTKG N/A
  • Revenue Growth
  • NXL 26.00
  • XTKG 51.59
  • 52 Week Low
  • NXL $0.30
  • XTKG $0.08
  • 52 Week High
  • NXL $4.49
  • XTKG $2.14
  • Technical
  • Relative Strength Index (RSI)
  • NXL 42.81
  • XTKG 37.62
  • Support Level
  • NXL $2.80
  • XTKG $0.56
  • Resistance Level
  • NXL $3.54
  • XTKG $0.68
  • Average True Range (ATR)
  • NXL 0.38
  • XTKG 0.10
  • MACD
  • NXL -0.02
  • XTKG -0.01
  • Stochastic Oscillator
  • NXL 14.53
  • XTKG 10.95

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

About XTKG X3 HOLDINGS CO LTD

X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.

Share on Social Networks: